Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...

A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

B cells from peripheral blood of patients undergoing BCG treatment were characterized using multispectral flow cytometry.

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’Topline safety data of SB101 Phase 1 study expected ...

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition ...

The Food and Drug Administration granted a fast track designation to IBI363 for patients with unresectable advanced or ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial ...